《大行報告》匯豐研究上調新秀麗(01910.HK)目標價至24元 評級「買入」
匯豐環球研究發表報告指,新秀麗(01910.HK)今年第三季的經調整EBITDA利潤率爲13%,距疫情前水平的約16%不遠。此證明在亞洲經濟低迷等情況下,集團實施的成本削減措施持續令人印象深刻。
該行表示,雖然歐洲新型肺炎確診個案正在增加,但集團北美及歐洲市場的情況已有改善,管理層相信第四季經調整EBITDA利潤率可有約15%的增長,並可將此水平持續至明年。
匯豐研究上調新秀麗股份目標價,由21元升至24元,評級維持「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.